Practical management of myelofibrosis with ruxolitinib

E-ISSN： 1445-5994|45|12|1221-1230

ISSN： 1444-0903

Source： INTERNAL MEDICINE JOURNAL, Vol.45, Iss.12, 2015-12, pp. : 1221-1230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sweet syndrome as terminal event in ruxolitinib‐treated myelofibrosis

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 307-307

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 29-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 162, Iss. 2, 2013-07 ,pp. : 229-239

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hayfever — practical management issues

By Ross Andrew Fleming Douglas

British Journal of General Practice, Vol. 54, Iss. 503, 2004-06 ,pp. : 412-414

Royal College of General Practitioners

Access to resources Recommend Favorite

Practical Management of Castleman's Disease

Acta Haematologica, Vol. 136, Iss. 1, 2016-04 ,pp. : 16-22

Karger

Access to resources Recommend Favorite